MedTrace Logo

The Effect of Antioxidants on Skin Blood Flow-BH4

NCT03680573 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-09-26

No results posted yet for this study

Summary

The goal of this study is to examine possible mechanisms of heightened vasoconstriction in Black/African American men and women as possible links to the elevated prevalence of cardiovascular dysfunction and disease. The main targets in this study are sources of oxidative stress

Conditions

Interventions

DRUG

Control: Lacated Ringers

This site will serve as the control site

DRUG

Apocynin

This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.

DRUG

Allopurinol

This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.

DRUG

BH4

This site will be use to locally supplement BH4.

DRUG

NG Nitro L Arginine Methyl Ester

L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

DRUG

Sodium Nitroprusside

SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

DRUG

Acetyl-ß-methylcholine chloride

Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.

Sponsors & Collaborators

  • The University of Texas at Arlington

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-08
Primary Completion
2018-05-05
Completion
2018-05-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680573 on ClinicalTrials.gov